Research Analysts Offer Predictions for SRPT Q3 Earnings

Key Points

• Analysts from Leerink Partners have raised their Q3 2025 earnings per share (EPS) forecast for Sarepta Therapeutics from ($1.08) to ($0.70), maintaining a "Hold" rating for the stock.
• Sarepta Therapeutics reported a significant quarterly revenue increase of 68.4% year-over-year, totaling $611.09 million, with earnings per share surpassing expectations at $2.02.
• Various analysts have mixed ratings on Sarepta Therapeutics, with eight recommending a Buy, fifteen a Hold, and six a Sell, indicating a generally cautious sentiment among investors.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a note issued to investors on Monday, September 8th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.70) for the quarter, up from their prior forecast of ($1.08). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics' Q4 2025 earnings at ($1.41) EPS, FY2025 earnings at ($3.99) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.69 EPS and FY2026 earnings at $2.91 EPS.

SRPT has been the subject of a number of other reports. Oppenheimer upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $30.00 to $37.00 in a report on Tuesday, July 29th. BMO Capital Markets boosted their price target on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a research note on Tuesday, July 29th. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. The Goldman Sachs Group lifted their price objective on shares of Sarepta Therapeutics to $19.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Morgan Stanley upped their target price on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $39.32.

Sarepta Therapeutics Trading Up 5.5%

SRPT stock traded up $0.96 during midday trading on Thursday, hitting $18.43. The stock had a trading volume of 4,026,870 shares, compared to its average volume of 6,322,104. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The firm has a market cap of $1.80 billion, a P/E ratio of -21.17 and a beta of 0.49. The business has a fifty day moving average price of $17.75 and a two-hundred day moving average price of $39.77. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same period in the prior year, the firm posted $0.07 EPS. The company's quarterly revenue was up 68.4% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. boosted its position in Sarepta Therapeutics by 347.8% during the second quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company's stock valued at $22,370,000 after buying an additional 1,016,069 shares during the period. Norges Bank bought a new position in Sarepta Therapeutics in the second quarter worth $15,619,000. Y Intercept Hong Kong Ltd lifted its position in Sarepta Therapeutics by 1,736.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company's stock valued at $14,880,000 after acquiring an additional 822,799 shares during the period. Aberdeen Group plc boosted its stake in Sarepta Therapeutics by 91.1% during the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company's stock worth $21,500,000 after acquiring an additional 592,125 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Sarepta Therapeutics by 438.0% during the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after acquiring an additional 580,123 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.